UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies

Clinical pharmacology and therapeutics, 2014-01, Vol.95 (1), p.24-31

2014

Volltextzugriff (PDF)

PD-L1 expression in nonclear-cell renal cell carcinoma

Annals of oncology, 2014-11, Vol.25 (11), p.2178-2184

2014

Volltextzugriff (PDF)

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Annals of oncology, 2020-08, Vol.31 (8), p.1030-1039

2020

Volltextzugriff (PDF)

Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions

Annals of oncology, 2017-07, Vol.28 (7), p.1484-1494

2017

Volltextzugriff (PDF)

Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System

Journal of clinical oncology, 2001-08, Vol.19 (16), p.3622-3634

2001

Volltextzugriff (PDF)

Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

Journal of clinical oncology, 2001-08, Vol.19 (16), p.3635-3648

2001

Volltextzugriff (PDF)

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts

British journal of cancer, 2013-02, Vol.108 (2), p.319-326

2013

Volltextzugriff (PDF)

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

Journal of clinical oncology, 1999-07, Vol.17 (7), p.2105-2116

1999

Volltextzugriff (PDF)

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies

Clinical cancer research, 1997-03, Vol.3 (3), p.409-417

1997

Volltextzugriff (PDF)

Interleukin-6 (IL-6) as an Anti-inflammatory Cytokine: Induction of Circulating IL-1 Receptor Antagonist and Soluble Tumor Necrosis Factor Receptor p55

Blood, 1994-01, Vol.83 (1), p.113-118

1994

Volltextzugriff (PDF)

Using Technology to Tackle Discrimination in Lending: The Role of Fintechs in the Paycheck Protection Program

AEA papers and proceedings, 2022-05, Vol.112, p.296-298

2022

Volltextzugriff (PDF)

Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma

British journal of cancer, 2011-06, Vol.105 (1), p.112-117

2011

Volltextzugriff (PDF)

Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)

Annals of oncology, 2018-10, Vol.29, p.viii724-viii725

2018

Volltextzugriff (PDF)

Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503

Urologic oncology, 2017-03, Vol.35 (3), p.117-118

2017

Volltextzugriff (PDF)

JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)

Annals of oncology, 2018-10, Vol.29, p.viii724-viii724

2018

Volltextzugriff (PDF)

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma

ESMO open, 2023-06, Vol.8 (3), p.101210-101210, Article 101210

2023

Volltextzugriff (PDF)

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma

Journal of immunotherapy (1997), 2012-01, Vol.35 (1), p.66-72

2012

Volltextzugriff (PDF)

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study

Journal of clinical oncology, 1998-05, Vol.16 (5), p.1743-1751

1998

Volltextzugriff (PDF)

Immunological Effects of Interleukin 12 Administered by Bolus Intravenous Injection to Patients with Cancer

Clinical cancer research, 1999-01, Vol.5 (1), p.9-16

1999

Volltextzugriff (PDF)

Clinical outcome of immune related hepatitis (IrHep) in patients with advanced melanoma (AM) treated with single agent or combination immune checkpoint inhibitors (ICIs)

Annals of oncology, 2018-10, Vol.29, p.viii433-viii434

2018

Volltextzugriff (PDF)

A phase Ia/IIb trial of the CXCR4 inhibitor X4P-001 and nivolumab for advanced renal cell carcinoma (RCC) that is unresponsive to nivolumab monotherapy

Annals of oncology, 2018-10, Vol.29, p.viii402-viii403

2018

Volltextzugriff (PDF)

KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)

Annals of oncology, 2018-10, Vol.29, p.viii307-viii307

2018

Volltextzugriff (PDF)

Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151

Annals of oncology, 2018-10, Vol.29, p.viii308-viii308

2018

Volltextzugriff (PDF)

PUSH-PULL THEORY IN BLACK AND WHITE: EXAMINING RACIAL DIFFERENCES IN FIRM STARTUPS BEFORE AND AFTER THE GREAT RECESSION

Journal of developmental entrepreneurship, 2021-09, Vol.26 (3)

ATKINS, RACHEL MB

2021

Volltextzugriff (PDF)

Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684

Journal of clinical oncology, 1997-06, Vol.15 (6), p.2351-2358

1997

Volltextzugriff (PDF)

1 – 25 von 2.006

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.728)
Mit Volltextzugriff
(1.671)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.999)
Deutsch
(5)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(1.055)
MEDLINE
(1.025)
Journals@Ovid
(847)
IngentaConnect_期刊（NSTL购买）
(775)
Single Journals
(767)
Elsevier ScienceDirect Journals Complete
(397)
IngentaConnect Journals
(344)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(265)
Wiley-Blackwell Journals
(206)
SpringerLink
(126)
Wiley Online Library Full Collection 2018
(116)
JSTOR
(91)
APS_美国物理学会期刊
(81)
Ebook Central Perpetual and DDA
(80)
eBooks on EBSCOhost
(78)
Oxford Journals
(77)
APS_美国物理学会过刊
(69)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(63)
Nature Journals Online
(46)
Nexis Uni (LexisNexis)
(38)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies

PD-L1 expression in nonclear-cell renal cell carcinoma

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions

Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System

Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies

Interleukin-6 (IL-6) as an Anti-inflammatory Cytokine: Induction of Circulating IL-1 Receptor Antagonist and Soluble Tumor Necrosis Factor Receptor p55

Using Technology to Tackle Discrimination in Lending: The Role of Fintechs in the Paycheck Protection Program

Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma

Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)

JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study

Immunological Effects of Interleukin 12 Administered by Bolus Intravenous Injection to Patients with Cancer

Clinical outcome of immune related hepatitis (IrHep) in patients with advanced melanoma (AM) treated with single agent or combination immune checkpoint inhibitors (ICIs)

A phase Ia/IIb trial of the CXCR4 inhibitor X4P-001 and nivolumab for advanced renal cell carcinoma (RCC) that is unresponsive to nivolumab monotherapy

KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)

Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151

PUSH-PULL THEORY IN BLACK AND WHITE: EXAMINING RACIAL DIFFERENCES IN FIRM STARTUPS BEFORE AND AFTER THE GREAT RECESSION

Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684

Suchergebnisse filtern